# CGEN catalysts: COMPUGEN LTD PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cgen/catalysts

> COMPUGEN LTD (CGEN) has 1 upcoming catalyst. The next is the COM701 interim data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CGEN?

COMPUGEN LTD (CGEN) has 1 upcoming catalyst. The next is the COM701 interim data readout, Q1 2027. Press release filed with the SEC (EX-99): "COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027" [Calendar and source filings](https://sec-api.dev/companies/cgen/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001178913-26-003754, https://www.sec.gov/Archives/edgar/data/1119774/000117891326003754/exhibit_99-1.htm (retrieved 2026-11-12). Last confirmed 2026-08-03. Cite: https://sec-api.dev/companies/cgen/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | COMPUGEN LTD |
| Ticker | CGEN (Nasdaq) |
| SEC CIK | 1119774 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/cgen |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q4 2024 | [GS-0321 trial start](https://sec-api.dev/pdufa/com503) | CGEN |  | scheduled | "On track to initiate Phase 1 trial evaluating COM503 (anti-IL18BP) in solid tumors in Q4 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1119774/000117891324003587/exhibit_99-1.htm)) |
| January 8, 2025 | [GS-0321 trial start](https://sec-api.dev/pdufa/com503) | CGEN |  | completed | "HOLON, ISRAEL - January 8, 2025 - Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the first patient was dosed in a Phase 1 clinical trial with COM503, a potential first-in-class antibody against IL-18 binding protein licensed by Compugen to Gilead." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1119774/000117891325000053/exhibit_99-1.htm)) |
| Q2 2025 | [COM701 interim data readout](https://sec-api.dev/pdufa/com701) | CGEN |  | scheduled | "We plan to start enrollment to this sub-trial in the second quarter of 2025 and we expect to share interim analysis data from this sub-trial in the second half of" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1119774/000117891325000679/zk2532769.htm)) |
| July 21, 2025 | [COM701 trial start](https://sec-api.dev/pdufa/com701) | CGEN | relapsed platinum sensitive ovarian cancer | completed | "Compugen Announces First Patient Dosed in COM701 Global" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1119774/000117891325002420/exhibit_99-1.htm)) |
| late 2026 | [COM701 interim data readout](https://sec-api.dev/pdufa/com701) | CGEN |  | scheduled | "H2 2026: data from projected interim analysis of single agent COM701 sub-trial 1 as maintenance therapy in relapsed platinum sensitive ovarian cancer" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1119774/000117891325002650/exhibit_99-1.htm)) |
| Q1 2027 | [COM701 interim data readout](https://sec-api.dev/pdufa/com701) | CGEN | platinum sensitive ovarian cancer with interim analysis now estimated in Q1 2027 | scheduled | "COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1119774/000117891326003754/exhibit_99-1.htm)) |

## Drugs

- [GS-0321](https://sec-api.dev/pdufa/com503): 
- [COM701](https://sec-api.dev/pdufa/com701): platinum sensitive ovarian cancer with interim analysis now estimated in q1 2027, platinum sensitive ovarian cancer in july 2025, relapsed platinum sensitive ovarian cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cgen/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CGEN catalysts: COMPUGEN LTD PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cgen/catalysts

```bibtex
@misc{secapidev_companies_cgen_catalysts_20261116,
  title        = {CGEN catalysts: COMPUGEN LTD PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cgen/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cgen_catalysts_20261116","title":"CGEN catalysts: COMPUGEN LTD PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cgen/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
